{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T03:06:20Z","timestamp":1768619180521,"version":"3.49.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"36","license":[{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"crossref","award":["no"],"award-info":[{"award-number":["no"]}],"id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>Postherpetic neuralgia (PHN) is a condition that results from nerve dysfunction following an episode of acute herpes zoster (shingles). Mirogabalin is a novel, selective oral \u03b1<jats:sub>2<\/jats:sub>\u03b4 ligand that demonstrated safety and efficacy in a multicenter, randomized, double-blind, placebo-controlled 14-week study in Asian patients with PHN. This 52-week, open-label extension study investigated the long-term safety and efficacy of flexible-dosage mirogabalin in Asian patients with PHN.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This open-label extension study enrolled patients who completed the placebo-controlled study. Patients started with a dose of 5\u200amg mirogabalin twice daily (BID), which was followed by a flexible dose of 10 or 15\u200amg BID. During the study, patients assessed their pain using the Short-Form McGill Pain Questionnaire (SF-MPQ). Adverse events were monitored throughout the study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of 239 enrolled patients, 184 (77.0%) completed the study and 185 patients (77.4%) received the 15 mg BID dose most during the treatment duration.<jats:sup\/> Most treatment-emergent adverse events (TEAEs) were mild or moderate. The most common TEAEs were nasopharyngitis, somnolence, dizziness, weight increased, and edema. All SF-MPQ scales decreased from baseline to week 52.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This study showed the safety and stable pain management of a long-term flexible dosing regimen of mirogabalin 10 or 15\u200amg twice daily for 52 weeks in patients with PHN.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical Trial Registered at ClinicalTrials.gov:<\/jats:title>\n            <jats:p>NCT02318719.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary for Table of Contents:<\/jats:title>\n            <jats:p>Mirogabalin\u2014a novel \u03b1<jats:sub>2<\/jats:sub>\u03b4 oral ligand\u2014was shown to be effective and well tolerated for treating postherpetic neuralgia (PHN) in an Asian multicenter, randomized, double-blind, placebo-controlled, 14-week study. This open-label, 52-week study was conducted as an extension of the double-blind study to demonstrate long-term safety and efficacy of mirogabalin.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000021976","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T14:21:03Z","timestamp":1598970063000},"page":"e21976","source":"Crossref","is-referenced-by-count":24,"title":["Long-term safety and efficacy of mirogabalin in Asian patients with postherpetic neuralgia"],"prefix":"10.1097","volume":"99","author":[{"given":"Jitsu","family":"Kato","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Nihon University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norimitsu","family":"Matsui","sequence":"additional","affiliation":[{"name":"Clinical Development Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9994-7955","authenticated-orcid":false,"given":"Yoshihiro","family":"Kakehi","sequence":"additional","affiliation":[{"name":"Clinical Development Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiko","family":"Murayama","sequence":"additional","affiliation":[{"name":"Asia Development Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Ohwada","sequence":"additional","affiliation":[{"name":"Biostatistics and Data Management Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,9,4]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.0000000000002808","article-title":"Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: a cohort study","volume":"87","author":"Forbes","year":"2016","journal-title":"Neurology"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2188\/jea.JE20140210","article-title":"Incidences of herpes zoster and postherpetic neuralgia in japanese adults aged 50 years and older from a community-based prospective cohort study: the shez study","volume":"25","author":"Takao","year":"2015","journal-title":"J Epidemiol"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40266-012-0014-3","article-title":"Diagnosing and managing postherpetic neuralgia","volume":"29","author":"Nalamachu","year":"2012","journal-title":"Drugs Aging"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1212\/01.wnl.0000259085.61898.9e","article-title":"The impact of neuropathic pain on health-related quality of life: review and implications","volume":"68","author":"Jensen","year":"2007","journal-title":"Neurology"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40261-017-0581-5","article-title":"Impact of herpes zoster and post-herpetic neuralgia on health-related quality of life in Japanese adults aged 60 years or older: results from a prospective, observational cohort study","volume":"38","author":"Mizukami","year":"2018","journal-title":"Clin Drug Investig"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"17537","DOI":"10.1073\/pnas.0409066103","article-title":"Identification of the a2d-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin","volume":"103","author":"Field","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pain.2006.04.022","article-title":"Calcium channel \u03b12\u03b4\u20131 subunit mediates spinal hyperexcitability in pain modulation","volume":"125","author":"Li","year":"2006","journal-title":"Pain"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"7025","DOI":"10.1074\/jbc.M114.548990","article-title":"Calcium channel alpha2delta1 proteins mediate trigeminal neuropathic pain states associated with aberrant excitatory synaptogenesis","volume":"289","author":"Li","year":"2014","journal-title":"J Biol Chem"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1523\/JNEUROSCI.0356-09.2009","article-title":"The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the \u03b12\u03b4 ligand pregabalin","volume":"29","author":"Bauer","year":"2009","journal-title":"J Neurosci"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/j.pain.0000000000001501","article-title":"Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients","volume":"160","author":"Kato","year":"2019","journal-title":"Pain"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0304-3959(87)91074-8","article-title":"The short-form McGill pain questionnaire","volume":"30","author":"Melzack","year":"1987","journal-title":"Pain"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/j.celrep.2018.02.021","article-title":"The alpha2delta-1-NMDA receptor complex is critically involved in neuropathic pain development and gabapentin therapeutic actions","volume":"22","author":"Chen","year":"2018","journal-title":"Cell Rep"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1124\/jpet.117.247551","article-title":"Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the alpha2delta subunit of voltage-gated calcium channels","volume":"365","author":"Domon","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/jcph.974","article-title":"Pharmacokinetics and safety of a single oral dose of mirogabalin in japanese subjects with varying degrees of renal impairment","volume":"58","author":"Kato","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1080\/14737175.2016.1202764","article-title":"Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use","volume":"16","author":"Calandre","year":"2016","journal-title":"Expert Rev Neurother"},{"key":"R17-20230915","first-page":"Cd011790","article-title":"Pregabalin for pain in fibromyalgia in adults","volume":"9","author":"Derry","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3109\/s10165-012-0803-x","article-title":"An open-label long-term phase III extension trial to evaluate the safety and efficacy of pregabalin in Japanese patients with fibromyalgia","volume":"23","author":"Ohta","year":"2013","journal-title":"Mod Rheumatol"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2147\/JPR.S63028","article-title":"An open-label, long-term study examining the safety and tolerability of pregabalin in Japanese patients with central neuropathic pain","volume":"7","author":"Onouchi","year":"2014","journal-title":"J Pain Res"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.2040-1124.2011.00122.x","article-title":"Efficacy and safety evaluation of pregabalin treatment over 52 weeks in patients with diabetic neuropathic pain extended after a double-blind placebo-controlled trial","volume":"2","author":"Satoh","year":"2011","journal-title":"J Diabetes Investig"},{"key":"R21-20230915","first-page":"961","article-title":"[Long-term efficacy and safety of pregabalin in patients with postherpetic neuralgia: results of a 52-week, open-label, flexible-dose study]","volume":"59","author":"Ogawa","year":"2010","journal-title":"Masui"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/BF03261976","article-title":"Pregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the west","volume":"35","author":"Ogawa","year":"2012","journal-title":"Drug Saf"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021976","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:10:22Z","timestamp":1694826622000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021976"}},"subtitle":["Results from an open-label extension of a multicenter randomized, double-blind, placebo-controlled trial"],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":21,"journal-issue":{"issue":"36","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000021976","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,4]]}}}